Nocebo effect and biosimilars in inflammatory bowel diseases: what's new and what's next?
Fiche publication
Date publication
août 2020
Journal
Expert opinion on biological therapy
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent
Tous les auteurs :
D'Amico F, Solitano V, Peyrin-Biroulet L, Danese S
Lien Pubmed
Résumé
The use of biosimilars for the treatment of patients with chronic inflammatory bowel diseases (IBD) showed to be a valid strategy to reduce the economic burden of biologics on health-care costs and to increase patient access to treatment. However, the nocebo effect constitutes an important limitation to the wide use of biosimilars.
Mots clés
Biosimilars, inflammatory bowel diseases, nocebo effect, switch
Référence
Expert Opin Biol Ther. 2020 Aug 28;: